- Prospective study of *Candida auris* nucleic-acids in wastewater solids in 190 wastewater
 treatment plants in the United States suggests widespread occurrence
- 3

Alessandro Zulli¹, Elana M. G. Chan¹, Bridgette Shelden², Dorothea Duong², Xiang-Ru S.
 Xu², Bradley J. White², Marlene K. Wolfe³, Alexandria B. Boehm^{1*}

6

7 1. Department of Civil and Environmental Engineering, Stanford University, 473 Via Ortega,

- 8 Stanford, California, 94305
- 9 2. Verily Life Sciences LLC, South San Francisco, CA, USA
- 10 3. Gangarosa Department of Environmental Health, Rollins School of Public Health, Emory
- 11 University, 1518 Clifton Rd, Atlanta, GA, USA, 30322
- 12
- 13 * Corresponding author: aboehm@stanford.edu
- 14 15

16

17 Abstract

18

19 Candida auris is an emerging, multidrug-resistant fungal pathogen that poses a significant 20 public health threat in healthcare settings. Despite yearly clinical cases rapidly increasing from 21 77 to 8,131 in the last decade, surveillance data on its distribution and prevalence remains 22 limited. We implemented a novel assay for C. auris detection on a nationwide scale 23 prospectively from September 2023 to March 2024, analyzing a total of 13,842 samples from 24 190 wastewater treatment plants across 41 U.S. states. Assays were extensively validated 25 through comparison to other known assays and internal controls. Of these 190 wastewater 26 treatment plants, C. auris was detected in the wastewater solids of 65 of them (34.2%) with 27 1.45% of all samples having detectable levels of C. auris. Detections varied seasonally, with 28 2.00% of samples positive in autumn versus 1.01% in winter (p<0.0001). The frequency of 29 detection in wastewater was significantly associated with states having older populations 30 (p<0.001), sewersheds containing more hospitals (p<0.0001), and sewersheds containing more 31 nursing homes (p<0.001). These associations are in agreement with known C. auris 32 epidemiology. This nationwide study demonstrates the viability of wastewater surveillance for C. 33 auris surveillance, and further highlights the value of wastewater surveillance when clinical 34 testing is constrained.

35

3637 Introduction

38 Healthcare associated infections are rapidly emerging as a global public health threat due to 39 increasing levels of antimicrobial resistance and an aging worldwide population (1-3). Among 40 these infections, Candida auris, first identified in 2009 in Japan, is an opportunistic, drug-41 resistant fungal pathogen with significant levels of associated morbidity and mortality (3-6). It 42 has now spread to over 40 countries and has been designated as a priority pathogen by both 43 international organizations, such as the World Health Organization (WHO), and national 44 organizations, such as the Center for Disease Control and Prevention (CDC) in the United 45 States, where it is now a nationally notifiable condition (4, 6, 7). The estimated crude mortality 46 rate within the United States for C. auris infections was 34% between 2017-2022 (5).

47

48 C. auris prevention and control efforts are exacerbated by the fungus' hardiness on fomites and 49 high levels of transmissibility (6–8). The fungus has been found to persist for at least 7 days on 50 both moist and dry surfaces, increasing the frequency and chance of transmission events in 51 healthcare settings (9, 10). Of particular concern are high-touch plastic surfaces within 52 healthcare facilities where C. auris was found to be viable for up to 14 days (10). In addition, C. 53 auris is resistant to many common disinfectants so proper decontamination protocols are 54 difficult and time intensive in already strained healthcare facilities (11). Further complicating 55 containment efforts are the different presentations in colonized individuals compared to those 56 with acute infections, with most colonized individuals presenting as asymptomatic (4). A lack of 57 screening in high-risk patients and misidentification of specimens as other Candida subspecies 58 has also contributed to the rapid spread of C. auris (5, 12). In the United States, clinical cases 59 rose from 77 between 2013-2016 to 8,131 in 2022 and are projected to continue rising (5, 13). 60

61 Despite this tremendous increase in cases and the accompanying screening efforts, clinically 62 available data are still sparse, with many institutions not speciating Candida cases resulting in 63 underreporting cases in long-term care facilities and nursing homes (13, 14). Many of these 64 facilities do not have the necessary equipment or human capital to implement speciation efforts 65 and screening, which has been shown to be a necessary part of successful containment efforts 66 (12). Alternative approaches to clinical surveillance are therefore necessary to better track both 67 the spread and severity of outbreaks. Wastewater represents a naturally composite sample 68 which is particularly useful for disease surveillance as it contains urine, feces, vomit, saliva, 69 sloughed skin cells, sputum, and other excretions. Wastewater surveillance has been 70 successfully used to track a wide variety of human pathogens including enterovirus, SARS-CoV-71 2, influenza A virus, and flavivirus (15–17). Like these viruses, C. auris has been detected in 72 urine and stool samples from colonized or infected individuals, though it is typically diagnosed

73	through presence in the blood or dermis of infected patients (4, 10, 18). Furthermore, recent
74	studies have demonstrated the persistence and subsequent detection of C. auris in wastewater
75	samples in Nevada and Florida (19). Early detection of this emerging pathogen through
76	environmental surveillance may complement clinical surveillance efforts and inform containment
77	and screening procedures (20).
78	
79	In this paper, we present the results of a United States-wide wastewater monitoring effort for C.
80	auris and compare the data to publicly available, recent, clinical case data. We also compare
81	results to available demographic indicators and healthcare facility locations. Detections of C.
82	auris in wastewater demonstrate wide geographical occurrence, and we demonstrate that these
83	wastewater detections appear to be associated with age and presence of hospitals and nursing
84	homes in adjacent communities. These results demonstrate the advantages of using
85	wastewater surveillance for the detection of emerging pathogens and for supplementing clinical
86	testing efforts.
87	
87 88	Methods
87 88 89	Methods
87 88 89 90	Methods RT-PCR assays. We designed a novel probe for <i>Candida auris</i> to use in conjunction with
87 88 89 90 91	Methods RT-PCR assays. We designed a novel probe for <i>Candida auris</i> to use in conjunction with previously published specific and sensitive forward and reverse primers (21). The assay targets
87 88 89 90 91 92	Methods RT-PCR assays. We designed a novel probe for <i>Candida auris</i> to use in conjunction with previously published specific and sensitive forward and reverse primers (21). The assay targets the region of the genome encoding the 5.8S ribosomal RNA, all of ITS2, and a fragment of 28S
87 88 89 90 91 92 93	Methods RT-PCR assays. We designed a novel probe for <i>Candida auris</i> to use in conjunction with previously published specific and sensitive forward and reverse primers (21). The assay targets the region of the genome encoding the 5.8S ribosomal RNA, all of ITS2, and a fragment of 28S ribosomal RNA. To design the probe, <i>C. auris</i> genome sequences were downloaded from the
87 88 89 90 91 92 93 94	Methods RT-PCR assays. We designed a novel probe for <i>Candida auris</i> to use in conjunction with previously published specific and sensitive forward and reverse primers (21). The assay targets the region of the genome encoding the 5.8S ribosomal RNA, all of ITS2, and a fragment of 28S ribosomal RNA. To design the probe, <i>C. auris</i> genome sequences were downloaded from the National Center for Biotechnology Information (NCBI) and aligned to identify conserved regions
87 88 90 91 92 93 94 95	Methods RT-PCR assays. We designed a novel probe for <i>Candida auris</i> to use in conjunction with previously published specific and sensitive forward and reverse primers (21). The assay targets the region of the genome encoding the 5.8S ribosomal RNA, all of ITS2, and a fragment of 28S ribosomal RNA. To design the probe, <i>C. auris</i> genome sequences were downloaded from the National Center for Biotechnology Information (NCBI) and aligned to identify conserved regions located between the primers. The probe was designed <i>in silico</i> using Primer3Plus
87 88 89 90 91 92 93 94 95 96	Methods RT-PCR assays. We designed a novel probe for <i>Candida auris</i> to use in conjunction with previously published specific and sensitive forward and reverse primers (21). The assay targets the region of the genome encoding the 5.8S ribosomal RNA, all of ITS2, and a fragment of 28S ribosomal RNA. To design the probe, <i>C. auris</i> genome sequences were downloaded from the National Center for Biotechnology Information (NCBI) and aligned to identify conserved regions located between the primers. The probe was designed <i>in silico</i> using Primer3Plus (https://primer3plus.com/). Parameters used in the design process (e.g., sequence length, GC
87 88 90 91 92 93 94 95 96 97	Methods RT-PCR assays. We designed a novel probe for <i>Candida auris</i> to use in conjunction with previously published specific and sensitive forward and reverse primers (21). The assay targets the region of the genome encoding the 5.8S ribosomal RNA, all of ITS2, and a fragment of 28S ribosomal RNA. To design the probe, <i>C. auris</i> genome sequences were downloaded from the National Center for Biotechnology Information (NCBI) and aligned to identify conserved regions located between the primers. The probe was designed <i>in silico</i> using Primer3Plus (https://primer3plus.com/). Parameters used in the design process (e.g., sequence length, GC content, and melt temperatures) are provided in Table S1. The primers and probe were then

99	panels, or cDNA sequences.	The <i>in silico</i> analysis was performed by excluding all <i>C. auris</i>	
----	----------------------------	--	--

- 100 genomes from a BLAST search, thereby only giving off-target matches (22).
- 101
- 102 The primers and probe were tested *in vitro* for specificity and sensitivity using a fungal panel
- 103 (NATCTVPOS-BD, Zeptomatrix Buffalo, NY) and Candida auris Satoh et Makimura (ATCC
- 104 MYA-5001) purchased from American Type Culture Collection (ATCC, Manassas, VA). The
- 105 fungal panel NATCTVPOS-BD includes chemically inactivated Candida albicans, C. krusei, C.
- 106 glabrata, and Trichomoniasis vaginalis. Nucleic acids were extracted from fungi using Chemagic
- 107 Viral DNA/RNA 300 Kit H96 for Chemagic 360 (PerkinElmer, Waltham, MA).
- 108

109 Nucleic acids were used undiluted as template in digital droplet RT-PCR (ddRT-PCR) singleton

assays for sensitivity and specificity testing in single wells. The concentration of targets used in

111 the *in vitro* specificity testing was between 10^3 and 10^4 copies per well. Negative RT-PCR

- 112 controls were included on each plate.
- 113

We used an RT-PCR assay for the in vitro sensitivity and specificity testing as the goal was to ultimately multiplex the *C. auris* assay in a panel that includes RNA-genome viruses. The implications of the use of RT-PCR, and a comparison to results obtained using PCR are further investigated, as described below. Regardless, this means the assay detects both DNA and RNA targets.

119

120 Clinical surveillance data. The National Notifiable Disease Surveillance System (NNDSS) is a 121 nationwide collaboration to which all levels of healthcare providers share health information 122 about nationally notifiable infectious and noninfectious diseases (23). Case reports are compiled 123 on a weekly basis using uniform case definitions from 50 states, the District of Columbia, New 124 York City, and 5 territories (American Samoa, Guam, Northern Mariana Islands, Puerto Rico,

125 U.S. Virgin Islands) (23). For this study, we used publicly available information on NNDSS for 126 Candida auris from 11 September 2023 to 1 March 2024 (https://data.cdc.gov/api/views/x9gk-127 5huc/rows.csv?accessType=DOWNLOAD). Dates of case determination varied but included the 128 following in order of preference: date of disease start, date of diagnosis, date of laboratory 129 result, date of first report to public health system, or date of state report (24). States which did 130 not report clinical case data were omitted from analyses. It should be noted that this database is 131 known to be incomplete as many local jurisdictions do not submit data; additional data on C. 132 auris cases or Candida cases may be available from other local or regional sources that are not 133 publicly available or currently updated. 134 135 Wastewater data: sample collection. Wastewater measurements were made prospectively as 136 part of a wastewater surveillance program. Between 11 September 2023 and 1 March 2024, 137 wastewater samples (either 24-hour composited influent or grab samples from the primary

138 clarifier, Table S1) were collected by wastewater treatment plant (WWTP) staff using sterile

139 containers. Samples were typically obtained approximately three times per week and shipped

140 overnight to the laboratory at 4°C where they were processed immediately with no storage.

Samples were collected from 190 distinct WWTPs across a total of 41 states over the course of
the study period (Figure 1). A total of 13,842 samples were collected and analyzed as part of
this study.

144

Wastewater data: pre-analytical processing. *C. auris* is expected to be associated with the solid phase of wastewater based on previous empirical measurements across liquid and solid phases in wastewater and its size (diameter = 2.5-5 µm), so in this study we made measurements in the solid phase of wastewater (25, 26). Details of the isolation of solids from the samples are provided in other peer-reviewed publications (27). In short, samples were centrifuged to dewater the solids. One aliquot of dewatered solids was used for nucleic-acid

151 extractions and another was used to determine the dry weight of the solids using an oven (27). 152 Approximately 75 mg of dewatered solids was added per milliliter of DNA/RNA shield (Zymo, 153 Irvine, CA) spiked with bovine coronavirus vaccine as a positive extraction control. This mixture 154 of solids and buffer was previously shown to have minimal inhibition.(28) The mixture was 155 homogenized after the addition of grinding balls, and centrifuged; the supernatant was used 156 immediately for nucleic-acid extractions. Nucleic-acids were extracted from 6-10 replicate 157 aliquots of the supernatant using the Chemagic Viral DNA/RNA 300 kit H96 for the Perkin Elmer 158 Chemagic 360 (Perkin Elmer, Waltham, MA) followed by PCR inhibitor removal with the Zymo 159 OneStep-96 PCR Inhibitor Removal kit (Zymo Research, Irvine, CA). Whether 6 or 10 replicates 160 were used is specified in Table S1. The suspension volume entered into the nucleic-acid 161 extraction process was 300 µl and 50 µl of nucleic-acids were retrieved after the inhibitor 162 removal kit. Negative extraction controls consisted of BCoV-vaccine spiked DNA/RNA Shield. 163 Nucleic-acids were used immediately as template in PCR as described next, with no storage. 164

165 Wastewater data: analytical processing. We used droplet digital reverse transcription 166 polymerase chain reaction (ddRT-PCR) to measure nucleic-acids in wastewater. We measured 167 pepper mild mottle virus (PMMoV) as an endogenous positive control as concentrations tend to 168 be extremely elevated in wastewater samples; we measured BCoV as an endogenous, spiked-169 in control (28–30). Methods applied to wastewater solids to measure PMMoV and BCoV in a 170 duplex reaction are provided in detail elsewhere (27). The C. auris assay (Table 1) was run in 171 multiplex using a probe-mixing approach. The exact assays that C. auris was multiplexed with 172 varied slightly over the duration of the project for some of the plants (information is provided in 173 Table S2). Multiplexing C. auris with these targets did not affect C. auris guantification (see SI 174 Figure S1). The results from those other assays are not provided herein. The PMMoV/BCoV 175 duplex and C. auris multiplex assays were run on 96-well plates. Each 96-well PCR plate of 176 wastewater samples included PCR positive controls for each target assayed on the plate in 1

- 177 well, PCR negative no template controls in two wells, and extraction negative controls in two
- 178 wells. PCR positive controls consisted of C. auris DNA. Each of the 6 or 10 replicate nucleic-
- acid extracts were run in their own wells to measure C. auris. Two randomly selected or 10
- 180 replicate nucleic-acid extracts were run in their own wells to measure PMMoV and BCoV (Table

181 S1).

182

Table 1. Primers and probes used in this study for detection of *C. auris* nucleic acids. Primers
and probes were purchased from Integrated DNA Technologies (Coralville, IA, USA). The

- probes contained fluorescent molecule HEX and quenchers (5' HEX/ZEN/3' IBFQ); HEX,
- 186 hexachloro-fluorescein; ZEN, a proprietary internal quencher from Integrated DNA Technologies
- 187 (Coralville, IA, USA); and IBFQ, Iowa Black FQ. Amplicon size is 163 basepairs.
- 188

Forward	CGCACATTGCGCCTTGGGGTA
Reverse	GTAGTCCTACCTGATTTGAGGCGAC
Probe	CTTCTCACCAATCTTCGCGGT

189 190

191 ddRT-PCR was performed on 20-µl samples from a 22 µl-reaction volume, prepared using 5.5 192 µl of template mixed with 5.5 µl of One-Step RT-ddPCR Advanced Kit for Probes (Bio-Rad 193 1863021), 2.2 µl of 200 U/µl Reverse Transcriptase, 1.1 µl of 300 mM dithiothreitol (DTT), and 194 primers and probes mixtures at a final concentration of 900 nM and 250 nM, respectively. 195 Primer and probes for assays were purchased from Integrated DNA Technologies (IDT, San 196 Diego, CA) (Table 1). C. auris was measured in reactions with undiluted template whereas 197 PMMoV and BCoV were run on template diluted 1:100 in molecular grade water. It is important 198 to note that an RT step was used because during the prospective study, we were measuring a 199 large number of RNA genome viruses. Therefore, the C. auris target quantified should be 200 interpreted as copies of RNA plus DNA. 201

202 Droplets were generated using the AutoDG Automated Droplet Generator (Bio-Rad, Hercules,

203 CA). PCR was performed using Mastercycler Pro (Eppendforf, Enfield, CT) with with the

204 following cycling conditions: reverse transcription at 50°C for 60 minutes, enzyme activation at 205 95°C for 5 minutes, 40 cycles of denaturation at 95°C for 30 seconds and annealing and 206 extension at 59°C (for C. auris) or 56°C (for PMMoV and BCoV) for 30 seconds, enzyme 207 deactivation at 98°C for 10 minutes then an indefinite hold at 4°C. The ramp rate for 208 temperature changes were set to 2°C/second and the final hold at 4°C was performed for a 209 minimum of 30 minutes to allow the droplets to stabilize. Droplets were analyzed using the 210 QX200 or the QX600 Droplet Reader (Bio-Rad). A well had to have over 10,000 droplets for 211 inclusion in the analysis. All liquid transfers were performed using the Agilent Bravo (Agilent 212 Technologies, Santa Clara, CA).

213

Thresholding was done using QuantaSoft™ Analysis Pro Software (Bio-Rad, version 1.0.596) 214 215 and QX Manager Software (Bio-Rad, version 2.0). Replicate wells were merged for analysis of 216 each sample. In order for a sample to be recorded as positive, it had to have at least 3 positive 217 droplets. Concentrations of RNA targets were converted to concentrations in units of copies 218 (cp)/g dry weight using dimensional analysis. The total error is reported as standard deviations. 219 Three positive droplets across 6 merged wells corresponds to a concentration between ~1000 220 cp/g; the range in values is a result of the range in the equivalent mass of dry solids added to 221 the wells. Data collected as part of the study are available from the Stanford Digital Repository 222 (https://purl.stanford.edu/hv291tt0888).

223

Wastewater: Confirmatory analyses. We selected seven samples (Table S3) with relatively high concentrations of *C. auris*, as measured above, to test another published *C. auris* assay by Barber et al. (25) for detecting *C. auris* in wastewater. The assay used by Barber et al. targets the same region of the *C. auris* genome as the assay in Table 1 but uses different primers and probes (Table S4) (25). Archived nucleic acid extracts, stored at -80°C, from those samples were thawed and then run as template using the Barber et al. assay as well as the assay

230 described herein (Table 1). The samples were run in duplex with an assay that targets the N 231 gene of SARS-CoV-2 (28). C. auris was run using a probe labeled with fluorescein amidite 232 (FAM). The methods described above for the analytical procedures (number of replicate wells, 233 negative and positive controls) were used. 234 235 These same seven samples were assayed with and without the reverse transcription step. 236 Nucleic-acid extracts were thawed and run exactly as described for the prospective study 237 except that the RT and DTT were not added to the mastermix. 238 239 We selected a subset of five of the seven samples (Table S3) for Sanger sequencing of the 240 PCR amplicon. One µl of archived (at -80°C) nucleic acid extracts was used as the template in a 241 50-µl PCR reaction prepared according to manufacturer's protocol with Q5® High-Fidelity 2X 242 Master Mix (New England Biolabs, Ipswich, MA) using the primers in Table 2. The thermocycler 243 program was run at an annealing temperature of 67°C for 30 seconds and extension at 72°C for 244 30 seconds. C. auris DNA was used as a positive control. PCR products were run on a 2% 245 agarose gel stained with SYBR Safe gel stain (Thermofisher, Fremont, CA) and amplicons of 246 the expected size (259 bp) were excised and gel purified using Zymo gel DNA recovery kit 247 (Irvine, CA). The purified DNA was then sent to Molecular Cloning Laboratories (South San

Francisco, CA) for sanger sequencing. Sequences were downloaded and aligned with *C. auris*

249 genomes using Snapgene software.

250



253

256

Figure 1. Location of wastewater treatment plants (WWTPs) with *Candida auris* DNA data included in the paper. Each blue dot represents the location of a WWTP.

257 **Demographic data.** *C. auris* hospitalizations are most common among older adults (5). We

used 5-year estimates from the 2022 American Community Survey (ACS) at the state level to

identify the median age of states with participating WWTPs (n = 41 states) (31).

260

261 Hospitals and nursing homes data. C. auris is particularly a concern in hospitals and nursing

homes (5, 14, 20). We obtained the locations of hospitals and nursing homes in the United

263 States from the US Department of Homeland Security's Homeland Infrastructure Foundation-

- Level Data (HIFLD) database (<u>https://gii.dhs.gov/HIFLD</u>) (32, 33). We selected all types of
- hospitals and nursing homes with an "open" status and then determined the number of hospitals
- and nursing homes in each sewershed using the Tabulate Intersection geoprocessing tool in
- ArcGIS Pro (version 3.1.1). Sewershed boundaries were provided by most WWTPs (n = 115).

268 For WWTPs that did not provide a sewershed (n = 75), we approximated sewershed boundaries 269 based on the zip codes serviced by the WWTP and USA ZIP Code Boundaries geospatial data 270 set published by Esri (Source: TomTom, US Postal Service, Esri) (34). 271 272 **Data analysis.** We made comparisons on the basis of percent of positive detections in 273 wastewater. Percentage of positive detections of C. auris was calculated by counting all positive 274 observations for a single WWTP and dividing by the total number of observations. Wastewater 275 measurements in each state were aggregated by Morbidity and Mortality Weekly Report 276 (MMWR) week, and we calculated the percentage of wastewater measurements that were 277 positive for C. auris each week. 278 279 Spearman's rank correlation coefficients were used to assess the association between weekly 280 (MMWR weeks) publicly available NNDSS clinical data and wastewater percent positive 281 detections (hereafter "detections") of C. auris for each state (n=18 states with wastewater and 282 clinical data). Case data from NNDSS, available on a weekly basis for each state, was used 283 after adjusting for population (cases per million people, Fig 2a). 284 285 We tested whether concentrations measured by the assay presented in Table 1 were different 286 from those measured by the Barber et al. assay using RT-ddPCR on 9 representative samples 287 (Table S3, Figure S2) (25). We ran the same samples using RT-ddPCR and ddPCR with no RT 288 step (Table S3, Figure S2). Differences between these controls were assessed using a paired t-289 test. 290 291 We also assessed the relationship between C. auris percent positive detections and several 292 other contextual and demographic factors. We explored seasonality by assessing C. auris 293 detections in wastewater samples collected in fall (defined as Sept 1 to Nov 30) and winter

294 (defined as Dec 1 to Feb 29). We then assessed the association between C. auris detections 295 and age at the state level. We grouped WWTPs by those in states with a median age less than 296 versus greater than or equal to the national median age (39 years) (31). Lastly, we assessed 297 the association between C. auris detections and hospitals and nursing homes at the sewershed 298 level. We grouped WWTPs by those with a sewershed intersecting (1) less than versus greater 299 than or equal to the median number of hospitals among all sewersheds (median: 1 hospital) and 300 (2) less than versus greater than or equal to the median number of nursing homes among all 301 sewersheds (median: 7 nursing homes). For seasonality, we compared the percentage of 302 wastewater samples positive for C. auris in each season. For age, hospitals, and nursing 303 homes, we compared the percentage of wastewater samples that were positive for C. auris 304 across WWTPs in the less than median group versus the greater than or equal to median group. 305 The null hypothesis tested for each of these variables was that there were no differences 306 between the two groups.

307

Statistical significance and 95% confidence intervals between the groups described above were assessed through bootstrapping (35, 36). For each variable and group, a distribution of values was generated through random sampling with replacement 10,000 times. Significance was then calculated using the proportion of values below our calculated statistic (i.e. whether the calculated statistics were above the 95% confidence intervals). This same method was used when assessing differences between assays (Fig S2) and seasonal differences in detection. In those cases, grouping was done based on assay and season, respectively.

315

316 Results

317

318 QA/QC. The *C. auris* assay was found to be sensitive and specific. The *in silico* analysis
319 indicated no primer or probe sequence was more than an 85% match to off-target matches, and

there was no overlap found between combinations of forward primer off-targets, reverse primer
off-targets, and probe off-targets. These factors indicate a high level of specificity in the primerprobe combination used. The in vitro testing confirmed sensitivity and specificity of the *C. auris*assay as *C. auris* nucleic-acids were positive and the remaining non-target nucleic-acids were
negative.

325

326 Results are reported following the Environmental Microbiology Minimal Information (EMMI)

327 guidelines (see SI and Figure S3).(37) All positive and negative controls performed as expected,

328 indicating acceptable assay performance. Median (IQR) BCoV recoveries across all wastewater

329 samples were 1.08 (0.82, 1.43) indicating good recovery across all samples. Recoveries

330 exceeding 1 are the result of uncertainties in the measurement of BCoV added to the buffer

331 matrix. PMMoV levels were elevated in all samples indicating lack of gross extraction failures

332 (median = 4.8×10^8 cp/g, min = 5.0×10^5 cp/g, max = 2.02×10^{11} cp/g).

333

As a further validation step, *C. auris* was quantified in a subset of samples also using the Barber et al. assay (Figure S2) (25). Concentrations measured by the two assays closely matched, with no statistically significant differences (p>0.05). Comparisons between concentrations measured using RT-ddPCR and ddPCR showed similar results (Figure S2); no significant differences were found (p>0.05). Additionally, the PCR amplicons obtained using the forward and reverse primers were sequenced and the sequences matched the *C. auris* genome segment targeted (Figure S4).

341

342 **National Overview**. The study period spanned 11 September 2023 to 1 March 2024.

343 Wastewater data were available from 190 distinct WWTPs in 41 states (Table S1). The number

of WWTPs in these states ranged between 1–57 WWTPs (median: 2 WWTPs), with population

345 coverage of the sewersheds ranging from 0.13% to 59.5% of the population of each individual

346	state (median: 5.75%). The number of wastewater samples collected and analyzed from
347	individual WWTPs ranged between 23–173 samples (median: 72 samples) during the study
348	period. In total, 13,842 wastewater samples were collected and analyzed across all WWTPs
349	during the study period. C. auris concentrations in these samples ranged from below the limit of
350	detection to 1,456,751 cp/g, with 1.45% (n = 200 samples) of samples above the lowest
351	detectable concentration. Sixty five (34.21%) WWTPs across 26 states had at least one
352	detectable C. auris concentration during the study period, and the percentage of positive
353	samples from these WWTPs ranged between 0.58%–46.48% (median: 1.49%). Time series
354	heatmaps of <i>C. auris</i> detections at each of the 190 WWTPs are provided in Figure S5.
355	Seasonally, 2.00% (n=6754) of observations were positive during autumn (defined as Sep 1 to
356	Nov 30), and 1.01%(n=7245) of observations were positive during winter (defined as Dec 1 to
357	Feb 29). This difference was statistically significant when assessed by a bootstrapping
358	approach (p<0.0001).
359	
360	Clinical data from the National Notifiable Disease Surveillance System (NNDSS) were

361 downloaded for comparison to wastewater data, and no significant correlations were found 362 between wastewater detections and population adjusted clinical case rates (Spearman's rho 363 between -0.10 and 0.23 for the 18 states, all p>0.05). Several states had obvious divergence 364 between wastewater positivity rates and population adjusted NNDSS clinical case rates (Figure 365 2). For example, in Maine, 13.3% of wastewater samples were positive for C. auris despite not 366 reporting any clinical cases during the study period to NNDSS (Figure 2). Twelve states which 367 did not report C. auris cases to the NNDSS were found to have positive detections of C. auris. 368 Figure 3 shows percentage positive detections as a function of population normalized clinical 369 cases and highlights the limited clinical data available.

370





b. Wastewater



371 372 Figure 2: Map showing percentage of positive wastewater samples and population normalized 373 case numbers from NNDSS across the United States. Figure 2a shows the normalized number 374 of cases per million in each state as reported to NNDSS during the study period. Figure 2b 375 shows the percentage of positive wastewater samples in each of the states surveilled during the 376 study period. Yellow represents low normalized values while black represents high normalized 377 values. Gray states represent areas without available data.

- 378
- 379



380 381

Figure 3. Comparison of wastewater percent positive detections and total clinical cases as reported by NNDSS. Only states with clinical data reported to NNDSS are included. Each labeled point represents the percentage of positive wastewater samples in that state and the number of cases reported to NNDSS. The state abbreviation is above each data point.

386 **Population demographics and healthcare facility locations and Candida auris.**

387 WWTPs were grouped using three separate statistics: median age of the state, number of

hospitals in the sewershed, and number of nursing homes in the sewershed (Fig 4). The median

389 age in the United States is 39 years as of the latest American Community Survey (ACS) data

- 390 (31). Seventy-eight WWTPs were located in a state with a median age at or above the national
- 391 median age; 112 WWTPs were located in a state with a median age below the national median
- 392 age. As shown in **Figure 4a**, among WWTPs in states with a median age at or above the
- national median age, 2.03% (95% CI: [0.80-3.50]) of all wastewater samples were positive for *C*.
- *auris*. Among WWTPs in states with a median age below the national median age, 0.83% (95%)
- 395 CI: [0.34-1.38]) of all wastewater samples were positive for *C. auris*. This difference was
- 396 statistically significant when assessed by bootstrapping (p < 0.001).
- 397

398 The median number of hospitals in the sewersheds was 1 hospital (range: 0–74 hospitals). WWTPs were grouped by whether they contained 0 hospitals (fewer than the median, n = 54) or 399 400 1 or more hospitals in their sewersheds (equal to or greater than the median, n = 136). We 401 found that 1.78% (95% CI: [0.92-2.90], n = 10,019) of samples from WWTPs with at least 1 hospital in their sewersheds were positive for C. auris whereas 0.62% (95% CI: [0.34-1.11], n = 402 403 3.819) of samples from WWTPs with no hospital in their sewershed were positive for C. auris 404 (Figure 4b). This difference was significant when assessed by bootstrapping (p < 0.0001). 405 406 The median number of nursing homes in the 190 sewersheds was 7 (range: 0-420 nursing 407 homes). WWTPs were grouped by whether they contained 0-6 nursing homes (fewer than the 408 median, n = 91) or 7 or more nursing homes in their sewersheds (equal to or greater than the 409 median, n = 99). We found that 1.92% (95% CI: [0.89–3.46], n = 7,544) of samples from 410 WWTPs with 7 or more nursing homes in their sewersheds were positive for C. auris whereas 411 0.87% (95% CI: [0.47–1.47], n = 6.294) of samples from WWTPs with 0–7 nursing homes in 412 their sewersheds were positive for *C. auris* (Figure 4c). This difference was significant when 413 assessed by bootstrapping (p < 0.001). 414





Figure 4. Comparison of wastewater detections across different groups. *** indicates p<0.001, 416 417 **** indicates p<0.0001. Figure 4a shows the percentage of positive samples for states at or 418 above the median age compared to those below. Figure 4b shows the percentage of positive 419 samples when grouped by number of hospitals at the sewershed level. Figure 4c shows the 420 same statistic when grouped by number of nursing homes, again at the sewershed level. Error 421 bars represent 95% confidence intervals derived from the bootstrapping approach.

423424 Discussion

425

426 Previous studies at the sewershed scale have shown that detection of *C. auris* in wastewater is 427 indicative of ongoing outbreaks in the contributing population (19, 25). To our knowledge, this 428 study represents the first nationwide wastewater monitoring effort of C. auris and comparison to 429 national clinical case data (23). We first demonstrate the sensitivity and specificity of the assay 430 used in this study through comparisons to published assays, sequencing (Figure S2, S4), and in 431 silico analyses. The widespread detection of C. auris in wastewater suggests a significant gap in 432 clinical case data reported to the NNDSS. Indeed, it is known that many local jurisdictions do 433 not provide data for inclusion in NNDSS. We found that C. auris detections are more frequent in 434 states with older populations and in sewersheds with higher numbers of nursing homes and 435 hospitals. These findings are consistent with C. auris infections being more common in older. 436 more susceptible populations and further support the assertion that clinical case data may be 437 incomplete.

438

439 C. auris has gone from initial detection in the United States in 2013 to being declared an 440 "Urgent" and notifiable pathogen in 2019 by the United States (CDC) (14, 20, 38). The rate of 441 testing volume and clinical positives has rapidly increased, with 17 states identifying their first C. 442 auris cases between 2019 to 2021 (14). Despite this, clinical testing for C. auris is far from 443 ubiquitous and not conducted uniformly across the United States (14, 39). On-site PCR testing 444 of clinical specimens is rare, and samples often have to be sent to public health or reference 445 laboratories, further increasing the cost of testing and the turnaround time before the data 446 reaches public health officials (39). Detections of C. auris nucleic-acids in wastewater collected 447 throughout the United States demonstrate a need for increased clinical testing and reporting

448 capacity, and the capability of wastewater testing to serve as a sentinel surveillance mechanism449 for emerging pathogens.

450

451 C. auris is an opportunistic pathogen that often infects the elderly and immunocompromised 452 within long-term healthcare facilities (10, 20, 40). Following our detection of C. auris, we 453 investigated potential demographics and healthcare facilities related to its pathology using data 454 from the ACS and US Department of Homeland Security's HIFLD database (31, 41). We 455 analyzed age, number of hospitals, and number of nursing homes as plausible factors impacting 456 the presence of *C. auris* within a sewershed or state. We found significant differences between 457 the percentage of positive detections of *C. auris* in states with a median age less than versus 458 greater than or equal to the national median age. Similarly, we found significant differences 459 between the percentage of positive detections of C. auris in sewersheds with less than versus 460 areater than or equal to the median number of hospitals and nursing homes. States with a 461 population above the national median age were more than three times as likely to detect C. 462 auris in a given wastewater sample. At the sewershed level, locations with 1 or more hospitals 463 had three times the amount of *C. auris* detections than locations with no hospitals. Similarly, 464 sewersheds with greater than or equal to the median number of nursing homes had over twice 465 as many detections of *C. auris* as those with fewer than the median number of nursing homes. 466 These findings are consistent with the known epidemiology of *C. auris*, as infected patients' 467 median age is 68 and outbreaks are prevalent in long-term healthcare facilities and nursing 468 homes (5, 14). The presence of an at-risk population appears to be strongly associated with C. 469 auris wastewater detections, suggesting public health efforts are appropriately focused on these 470 at-risk populations.

471

472 Significant steps were taken to ensure the validity of detection results. A similar assay was used
473 by Barber et al. for the detection of *C. auris* in southern Nevada during an outbreak (25). We

474 tested nine samples from three different states using both the assay presented in this study and 475 the one used by Barber et al. (25). No statistically significant difference was found between the 476 two assays, which both targeted the same region of an internally transcribed spacer region. Our 477 assay was further validated using a subset of 5 of these 9 samples through sequencing. The 478 amplicons generated by our forward and reverse primers independently and accurately matched 479 the reference amplicon, indicating specific amplification (Figure S4). Together, these results 480 demonstrate that the assay used in this study is highly specific. Finally, we used an RT-PCR 481 assay to detect C. auris which means the assay should detect both RNA and DNA. We 482 measured some samples using both RT-PCR and PCR and the results indicated that most of 483 the target nucleic acids in those samples were DNA. This was somewhat surprising since we 484 expect the DNA target (located in the region of the genome that encodes ribosomal RNA) 485 should be transcripted into RNA by C. auris. Future work will need to be done to further 486 investigate the relative proportion of target RNA versus DNA C. auris targets in wastewater. 487 Regardless, the use of an RT-PCR assay, allowing detection of both RNA and DNA, should 488 increase the sensitivity of the assay (by detecting both nucleic-acids) yet perhaps complicate 489 interpretation of measured concentrations. For this reason, we only use the data in 490 presence/absence format.

491

492 Overall, our results demonstrate that *C. auris* wastewater surveillance can provide timely 493 information on geographical distribution and help identify at-risk populations; wastewater data 494 can be available within 24-48 hours of sample collection. As an emerging disease, clinical 495 testing for C. auris largely depends on shipping samples to public health laboratories (7, 13, 14). 496 Wastewater surveillance can help fill this gap for municipalities and states without the capital to 497 fund testing systems, providing community level information as to the prevalence, and more 498 importantly, the spread of *C. auris*. These data are critical to public health responses, 499 particularly when dealing with pathogens that do not or did not have robust clinical testing

systems such as Dengue virus, SARS-CoV-2, and *C. auris* (14, 16, 17, 39). *C. auris* wastewater
surveillance data can then be used to implement stricter screening protocols, cleaning
protocols, and other non-pharmaceutical interventions that can prevent the spread of illness
amongst vulnerable populations (9, 10, 20).

504 There are limitations associated with this study. Importantly, the availability of clinical data was 505 limited due to the recent classification in 2018 of C. auris as a notifiable disease, making in-506 depth analyses of associations between wastewater detections and clinical data on infections 507 unfeasible. In addition, it is well understood that the NNDSS database may not contain all the 508 information on C. auris positive cases in the United States; local jurisdictions may have local 509 data to inform public health response to infections and those data were not available for this 510 work. Local jurisdictions are encouraged to use these wastewater data to compare to their local 511 case rates. Further, wastewater sampling was not uniform across the United States or within 512 individual states, which could introduce biases into the analyses. Within the demographic data 513 available at the sewershed level, information was limited as to the size of nursing homes and 514 hospitals, which might be important factors controlling associations with wastewater data on C. 515 auris. Lastly, we were unable to link specific wastewater concentrations to population-level 516 incidence. Further experiments are necessary to understand the shedding patterns of C. auris in 517 human excretions as to provide this direct link to disease occurrence in the contributing 518 population. These experiments are particularly important to the determination of the significance 519 of wastewater detections, as C. auris contributions to wastewater could potentially be from 520 colonized individuals or individuals with acute infection. Finally, an additional limitation is that we 521 cannot rule out the potential for C. auris detections in wastewater to be from zoonotic or 522 environmental sources. Detections have been shown to match underlying expected 523 demographic indicators such as age and presence of nursing homes, further lending credence 524 to the source of detections being human. While there is no evidence to support the possibility of 525 zoonotic or environmental contributions of C. auris nucleic-acids to wastewater, further research

526	is needed to see if such evidence might exist. There have been case reports of C. auris
527	infections in canines, and Candida spp. have been detected using culture and other molecular
528	methods from biofilms in sewer pipes (42-45). It should be noted that wastewater detection of
529	Candida auris collected at the wastewater treatment plant scale does not imply community-
530	spread of the pathogen, but is consistent with its presence in one or more individuals within the
531	sewershed.
532	
533	Acknowledgements. We acknowledge all the wastewater treatment plant staff who provided
534	samples for this project.

536 537 538								
539 540	Refe	References						
541	1.	Ageing and health. https://www.who.int/news-room/fact-sheets/detail/ageing-and-health.						
542		Retrieved 17 January 2024.						
543	2.	Hospital-Acquired Infections - ClinicalKey.						
544		https://www.clinicalkey.com/#!/content/playContent/1-s2.0-S0039610911001514. Retrieved						
545		16 January 2024.						
546	3.	Serra-Burriel M, Keys M, Campillo-Artero C, Agodi A, Barchitta M, Gikas A, Palos C,						
547		López-Casasnovas G. 2020. Impact of multi-drug resistant bacteria on economic and						
548		clinical outcomes of healthcare-associated infections in adults: Systematic review and						
549		meta-analysis. PLOS ONE 15:e0227139.						
550	4.	Ahmad S, Alfouzan W. 2021. Candida auris: Epidemiology, Diagnosis, Pathogenesis,						
551		Antifungal Susceptibility, and Infection Control Measures to Combat the Spread of						
552		Infections in Healthcare Facilities. Microorganisms 9:807.						
553	5.	Benedict K, Forsberg K, Gold JAW, Baggs J, Lyman M. Candida auris-Associated						
554		Hospitalizations, United States, 2017–2022 - Volume 29, Number 7—July 2023 - Emerging						
555		Infectious Diseases journal - CDC https://doi.org/10.3201/eid2907.230540.						
556	6.	Lone SA, Ahmad A. 2019. Candida auris—the growing menace to global health. Mycoses						
557		62:620–637.						
558	7.	2023. Surveillance for Candida auris Candida auris Fungal Diseases CDC.						
559		https://www.cdc.gov/fungal/candida-auris/c-auris-surveillance.html. Retrieved 17 January						
560		2024.						
561	8.	Sengupta S, Marimuthu K, Stewardson A, Harbarth S, Durante A, Singh S. 2020.						
562		Challenges in Identification of Candida auris in Hospital Laboratories: Comparison						
563		Between HIC and LMIC. Infect Control Hosp Epidemiol 41:s158–s158.						

564	9.	Piedrahita CT, Cadnum JL, Jencson AL, Shaikh AA, Ghannoum MA, Donskey CJ. 2017.
565		Environmental Surfaces in Healthcare Facilities are a Potential Source for Transmission of
566		Candida auris and Other Candida Species. Infect Control Hosp Epidemiol 38:1107–1109.
567	10.	Welsh RM, Bentz ML, Shams A, Houston H, Lyons A, Rose LJ, Litvintseva AP. 2017.
568		Survival, Persistence, and Isolation of the Emerging Multidrug-Resistant Pathogenic Yeast
569		Candida auris on a Plastic Health Care Surface. J Clin Microbiol 55:2996–3005.
570	11.	US EPA O. 2020. List P: Antimicrobial Products Registered with EPA for Claims Against
571		Candida Auris. Overviews and Factsheets. https://www.epa.gov/pesticide-registration/list-
572		p-antimicrobial-products-registered-epa-claims-against-candida-auris. Retrieved 25
573		January 2024.
574	12.	Karmarkar EN, O'Donnell K, Prestel C, Forsberg K, Gade L, Jain S, Schan D, Chow N,
575		McDermott D, Rossow J, Toda M, Ruiz R, Hun S, Dale JL, Gross A, Maruca T, Glowicz J,
576		Brooks R, Bagheri H, Nelson T, Gualandi N, Khwaja Z, Horwich-Scholefield S, Jacobs J,
577		Cheung M, Walters M, Jacobs-Slifka K, Stone ND, Mikhail L, Chaturvedi S, Klein L,
578		Vagnone PS, Schneider E, Berkow EL, Jackson BR, Vallabhaneni S, Zahn M, Epson E.
579		2021. Rapid Assessment and Containment of Candida auris Transmission in Postacute
580		Care Settings—Orange County, California, 2019. Ann Intern Med 174:1554–1562.
581	13.	2023. Tracking Candida auris Candida auris Fungal Diseases CDC.
582		https://www.cdc.gov/fungal/candida-auris/tracking-c-auris.html. Retrieved 17 January
583		2024.
584	14.	Worsening Spread of Candida auris in the United States, 2019 to 2021 Annals of Internal
585		Medicine. https://www.acpjournals.org/doi/full/10.7326/M22-3469. Retrieved 17 January
586		2024.
587	15.	Boehm AB, Hughes B, Doung D, Chan-Herur V, Buchman A, Wolfe MK, White BJ. 2022.
588		Wastewater surveillance of human influenza, metapneumovirus, parainfluenza, respiratory
589		syncytial virus (RSV), rhinovirus, and seasonal coronaviruses during the COVID-19

590 pandemic. preprint. Infectious Diseases (except HIV/AIDS).

- 16. Peccia J, Zulli A, Brackney DE, Grubaugh ND, Kaplan EH, Casanovas-Massana A, Ko AI,
- 592 Malik AA, Wang D, Wang M, Warren JL, Weinberger DM, Arnold W, Omer SB. 2020.
- 593 Measurement of SARS-CoV-2 RNA in wastewater tracks community infection dynamics.
- 594 Nat Biotechnol 38:1164–1167.
- 595 17. Wolfe MK, Paulos AH, Zulli A, Duong D, Shelden B, White BJ, Boehm AB. 2024.
- 596 Wastewater Detection of Emerging Arbovirus Infections: Case Study of Dengue in the
 597 United States. Environ Sci Technol Lett 11:9–15.
- 598 18. Pacilli M, Kerins JL, Clegg WJ, Walblay KA, Adil H, Kemble SK, Xydis S, McPherson TD,
- 599 Lin MY, Hayden MK, Froilan MC, Soda E, Tang AS, Valley A, Forsberg K, Gable P,

600 Moulton-Meissner H, Sexton DJ, Jacobs Slifka KM, Vallabhaneni S, Walters MS, Black

- 601 SR. 2020. Regional Emergence of Candida auris in Chicago and Lessons Learned From
- 602 Intensive Follow-up at 1 Ventilator-Capable Skilled Nursing Facility. Clin Infect Dis
- 603 71:e718–e725.

19. Babler K, Sharkey M, Arenas S, Amirali A, Beaver C, Comerford S, Goodman K, Grills G,

Holung M, Kobetz E, Laine J, Lamar W, Mason C, Pronty D, Reding B, Schürer S,

- 606 Schaefer Solle N, Stevenson M, Vidović D, Solo-Gabriele H, Shukla B. 2023. Detection of
- the clinically persistent, pathogenic yeast spp. Candida auris from hospital and municipal
 wastewater in Miami-Dade County, Florida. Sci Total Environ 898:165459.
- 609 20. 2023. Infection Prevention and Control for Candida auris | Candida auris | Fungal
- 610 Diseases | CDC. https://www.cdc.gov/fungal/candida-auris/c-auris-infection-control.html.
- 611 Retrieved 25 January 2024.
- 612 21. Kordalewska M, Zhao Y, Lockhart SR, Chowdhary A, Berrio I, Perlin DS. 2017. Rapid and
- Accurate Molecular Identification of the Emerging Multidrug-Resistant Pathogen Candida
 auris. J Clin Microbiol 55:2445–2452.
- 615 22. BLAST: Basic Local Alignment Search Tool. https://blast.ncbi.nlm.nih.gov/Blast.cgi.

616 Retrieved 29 February 2024.

- 617 23. National Notifiable Diseases Surveillance System (NNDSS) Healthy People 2030 |
- 618 health.gov. https://health.gov/healthypeople/objectives-and-data/data-sources-and-
- 619 methods/data-sources/national-notifiable-diseases-surveillance-system-nndss. Retrieved

620 26 January 2024.

- 621 24. Weston E (CDC/OID/NCIRD). Guidance on classifying STD case reports into MMWR
 622 week.
- 623 25. Barber C, Crank K, Papp K, Innes GK, Schmitz BW, Chavez J, Rossi A, Gerrity D. 2023.
- 624 Community-Scale Wastewater Surveillance of Candida auris during an Ongoing Outbreak

625 in Southern Nevada. Environ Sci Technol 57:1755–1763.

- 626 26. Roldan-Hernandez L, Boehm AB. 2023. Adsorption of Respiratory Syncytial Virus,
- 627 Rhinovirus, SARS-CoV-2, and F+ Bacteriophage MS2 RNA onto Wastewater Solids from

628 Raw Wastewater. Environ Sci Technol 57:13346–13355.

- 27. Boehm A, Wolfe M, Wigginton K, Bidwell A, White B, Duong D, Hughes B, Chan-Herur V,
- 630 Naughton C, Bischel H. 2023. Human viral nucleic acids concentrations in wastewater

solids from Central and Coastal California, USA. Boehm Res Group Stanf.

632 28. Human viral nucleic acids concentrations in wastewater solids from Central and Coastal
633 California USA | Scientific Data. https://www-nature-

634 com.stanford.idm.oclc.org/articles/s41597-023-02297-7. Retrieved 14 October 2023.

635 29. McClary-Gutierrez JS, Aanderud ZT, Al-faliti M, Duvallet C, Gonzalez R, Guzman J, Holm

636 RH, Jahne MA, Kantor RS, Katsivelis P, Kuhn KG, Langan LM, Mansfeldt C, McLellan SL,

- 637 Grijalva LMM, Murnane KS, Naughton CC, Packman AI, Paraskevopoulos S, Radniecki
- 538 TS, Roman FA, Shrestha A, Stadler LB, Steele JA, Swalla BM, Vikesland P, Wartell B,
- 639 Wilusz CJ, Wong JCC, Boehm AB, Halden RU, Bibby K, Vela JD. 2021. Standardizing
- 640 data reporting in the research community to enhance the utility of open data for SARS-
- 641 CoV-2 wastewater surveillance. Environ Sci Water Res Technol 7:1545–1551.

- 30. Rosario K, Symonds EM, Sinigalliano C, Stewart J, Breitbart M. 2009. Pepper mild mottle
- virus as an indicator of fecal pollution. Appl Environ Microbiol 75:7261–7267.
- 644 31. U.S. Census Bureau. S0101: Age and Sex Census Bureau Table. Am Community Surv
- 645 ACS 1-Year Estim Subj Tables Table S0101.
- 646 https://data.census.gov/table/ACSST1Y2022.S0101?q=median%20age%20by%20state&g
- 647 =010XX00US. Retrieved 12 February 2024.
- 648 32. Nursing Homes. https://hifld-geoplatform.hub.arcgis.com/datasets/geoplatform::nursing-
- 649 homes/about. Retrieved 13 March 2024.
- 650 33. Hospitals. https://hifld-geoplatform.hub.arcgis.com/datasets/geoplatform::hospitals/about.
- 651 Retrieved 13 March 2024.
- 652 34. USA ZIP Code Boundaries.
- https://hub.arcgis.com/datasets/d6f7ee6129e241cc9b6f75978e47128b_0/about. Retrieved
 6 March 2024.
- 655 35. Efron B. 1979. Bootstrap Methods: Another Look at the Jackknife. Ann Stat 7:1–26.
- 36. DICICCIO T, EFRON B. 1992. More accurate confidence intervals in exponential families.
 Biometrika 79:231–245.
- 658 37. Borchardt MA, Boehm AB, Salit M, Spencer SK, Wigginton KR, Noble RT. 2021. The
- 659 Environmental Microbiology Minimum Information (EMMI) Guidelines: qPCR and dPCR
- 660 Quality and Reporting for Environmental Microbiology. Environ Sci Technol 55:10210–
- 661 10223.
- 662 38. Centers for Disease Control and Prevention (U.S.). 2019. Antibiotic resistance threats in
 663 the United States, 2019. Centers for Disease Control and Prevention (U.S.).
- 39. Arenas S, Patel S, Seely SO, Pagan PP, Warde PR, Tamrakar LJ, Parekh DJ, Ferreira T,
- 265 Zhou Y, Gershengorn HB, Shukla BS. 2023. Operational impact of decreased turnaround
- times for Candida auris screening tests in a tertiary academic medical center. Antimicrob
- 667 Steward Healthc Epidemiol ASHE 3:e176.

668	40.	Schwartz IS,	Dingle TC.	2019.	Candida auris.	CMAJ	Can Med	Assoc J	191:E865.
-----	-----	--------------	------------	-------	----------------	------	---------	---------	-----------

- 669 41. HIFLD Open. https://hifld-geoplatform.hub.arcgis.com/pages/hifld-open. Retrieved 19
 670 March 2024.
- 42. White TC, Esquivel BD, Rouse Salcido EM, Schweiker AM, dos Santos AR, Gade L, Petro
- E, KuKanich B, KuKanich KS. 2024. Candida auris detected in the oral cavity of a dog in
- 673 Kansas. mBio 15:e03080-23.
- 43. Yadav A, Wang Y, Jain K, Panwar VAR, Kaur H, Kasana V, Xu J, Chowdhary A. 2023.

675 Candida auris in Dog Ears. J Fungi 9:720.

- 44. Cavalheiro M, Teixeira MC. 2018. Candida Biofilms: Threats, Challenges, and Promising
- 677 Strategies. Front Med 5:28.
- 45. Nobile CJ, Johnson AD. 2015. Candida albicans Biofilms and Human Disease. Annu Rev
 Microbiol 69:71–92.

680 681

682 683

684

685

686